Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from ELEVAI Labs Inc. ( (ELAB) ) is now available.
On February 7, 2025, Northstrive Biosciences presented its innovative obesity drug candidates, EL-22 and EL-32, at the UCLA Obesity Symposium. These drugs are designed to preserve muscle mass during weight loss, addressing a major concern with current obesity treatments. The presentation highlighted the unique mechanism of EL-22, which uses engineered probiotics to stimulate myostatin-specific immune responses, potentially revolutionizing treatments in the obesity sector.
More about ELEVAI Labs Inc.
Northstrive Biosciences, a subsidiary of PMGC Holdings Inc., operates in the biotechnology industry with a focus on developing therapeutics for obesity and aesthetics. Their primary products include drug candidates like EL-22, which targets obesity by preserving muscle mass during weight loss treatments, thereby addressing a significant market need.
YTD Price Performance: -25.40%
Average Trading Volume: 2,658,639
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $5.68M
For an in-depth examination of ELAB stock, go to TipRanks’ Stock Analysis page.
